Brokerages Set Tyra Biosciences, Inc. (NASDAQ:TYRA) PT at $30.50

Tyra Biosciences, Inc. (NASDAQ:TYRA) has been given an average rating of “Buy” by the six brokerages that are currently covering the company, Marketbeat reports. Six investment analysts have rated the stock with a buy recommendation. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $30.50.

Several equities analysts have commented on TYRA shares. HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price target on shares of Tyra Biosciences in a report on Monday, January 13th. UBS Group started coverage on Tyra Biosciences in a research note on Tuesday, January 7th. They issued a “buy” rating and a $28.00 target price for the company. Bank of America upgraded shares of Tyra Biosciences from a “neutral” rating to a “buy” rating and lifted their price target for the stock from $22.00 to $31.00 in a research note on Friday, October 18th. Finally, Wedbush restated an “outperform” rating and issued a $28.00 price objective on shares of Tyra Biosciences in a research note on Friday, October 25th.

Insider Activity

In other news, Director Nina S. Kjellson sold 7,779 shares of Tyra Biosciences stock in a transaction that occurred on Thursday, January 16th. The shares were sold at an average price of $16.29, for a total value of $126,719.91. Following the completion of the transaction, the director now owns 447,857 shares in the company, valued at approximately $7,295,590.53. The trade was a 1.71 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In the last quarter, insiders have sold 21,998 shares of company stock worth $344,818. Corporate insiders own 15.40% of the company’s stock.

Institutional Trading of Tyra Biosciences

Large investors have recently made changes to their positions in the business. US Bancorp DE acquired a new position in Tyra Biosciences during the 4th quarter worth about $50,000. China Universal Asset Management Co. Ltd. bought a new position in Tyra Biosciences in the 4th quarter worth approximately $149,000. Franklin Resources Inc. acquired a new position in Tyra Biosciences during the 3rd quarter worth $278,000. Valence8 US LP bought a new stake in shares of Tyra Biosciences during the third quarter worth $310,000. Finally, SG Americas Securities LLC bought a new stake in shares of Tyra Biosciences during the third quarter worth $311,000. Institutional investors own 84.14% of the company’s stock.

Tyra Biosciences Trading Down 3.8 %

TYRA opened at $12.67 on Friday. Tyra Biosciences has a 1-year low of $12.60 and a 1-year high of $29.60. The business has a 50 day moving average of $15.11 and a 200-day moving average of $18.81. The stock has a market capitalization of $641.10 million, a price-to-earnings ratio of -7.87 and a beta of 1.05.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.01). Equities analysts predict that Tyra Biosciences will post -1.57 EPS for the current year.

About Tyra Biosciences

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.